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Summary
Background Rare variants in the genes IL36RN, CARD14 and AP1S3 have been identi-
fied to cause or contribute to pustular skin diseases, primarily generalized pustu-
lar psoriasis (GPP).
Objectives To better understand the disease relevance of these genes, we screened
our cohorts of patients with pustular skin diseases [primarily GPP and palmoplantar
pustular psoriasis (PPP)] for coding changes in these three genes. Carriers of single
heterozygous IL36RN mutations were screened for a second mutation in IL36RN.
Methods Coding exons of IL36RN, CARD14 and AP1S3 were sequenced in 67 patients
– 61 with GPP, two with acute generalized exanthematous pustulosis and four with
acrodermatitis continua of Hallopeau. We screened IL36RN and AP1S3 for intragenic
copy-number variants and 258 patients with PPP for coding changes in AP1S3. Ele-
ven heterozygous IL36RN mutations carriers were analysed for a second noncoding
IL36RN mutation. Genotype–phenotype correlations in carriers/noncarriers of
IL36RN mutations were assessed within the GPP cohort.
Results The majority of patients (GPP, 64%) did not carry rare variants in any of
the three genes. Biallelic and monoallelic IL36RN mutations were identified in 15
and five patients with GPP, respectively. Noncoding rare IL36RN variants were
not identified in heterozygous carriers. The only significant genotype–phenotype
correlation observed for IL36RN mutation carriers was early age at disease onset.
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Additional rare CARD14 or AP1S3 variants were identified in 15% of IL36RN muta-
tion carriers.
Conclusions The identification of IL36RN mutation carriers harbouring additional
rare variants in CARD14 or AP1S3 indicates a more complex mode of inheritance
of pustular psoriasis. Our results suggest that, in heterozygous IL36RN mutation
carriers, there are additional disease-causing genetic factors outside IL36RN.
What’s already known about this topic?
• The genes IL36RN, CARD14 and AP1S3 have been implicated in pustular skin disease
with IL36RN having a major role.
• Most studies have analysed variants in different genes separately.
• Significant subsets of patients with a pustular skin disease carry a single heterozy-
gous mutation in IL36RN, leaving unanswered whether and how the variant is dis-
ease-contributing.
What does this study add?
• Intragenic copy-number variants or noncoding mutations in carriers of single
IL36RN mutations were not found.
• In total, 15% of patients with generalized pustular psoriasis (GPP) with IL36RN
mutations carried variants in CARD14 or AP1S3, providing evidence for a complex
inheritance.
• Lack of causal /disease-contributing variants in 64% of GPP patients suggests a role
for other, not yet identified genes.
• Genotype–phenotype correlation did not reveal significant correlations aside from
the presence of IL36RN mutations with age at onset.
What is the translational message?
• This study of three genes provides evidence that the inheritance of GPP is more
complex than previously understood.
• The role of known genes in GPP is rather limited, as almost two-thirds of patients
do not carry a variant in any of these genes.
• In palmoplantar pustular psoriasis, the percentage of noncarriers is even lower.
• Further genetic studies will reveal the diseases’ pathogenesis and provide a basis to
use/develop more specific treatments.
Within the past few years, variants in three genes have been
identified to be involved in the pathogenesis of pustular psoriasis
and other pustular skin diseases. Biallelic mutations in IL36RN
have been described as disease-causing in 21–41% of Asian/
European patients with generalized pustular psoriasis (GPP),1–3
indicating IL36RN mutations as a major pathogenic factor in
GPP.4,5 In some patients only a single mutation can be identified.
Mutations in IL36RN lead to a reduced function or loss of func-
tion of the interleukin (IL)-36 receptor-antagonist (IL-36Ra)
and therefore to an imbalance in the IL-36 pathway in favour of
proinflammatory IL-36 cytokines. This imbalance results in
increased activation of the IL-36 pathway with subsequent acti-
vation of the mitogen-activated protein kinases and production
of, for example, IL-8 and IL-6.4 The same IL36RN mutations are
also associated with other pustular skin diseases, acrodermatitis
continua of Hallopeau (ACH) and acute generalized exanthema-
tous pustulosis (AGEP),6,7 predominantly as single heterozygous
mutations. Evidence for an association with palmoplantar pustu-
lar psoriasis (PPP) is less consistent8,9 and no association was
identified with more common forms of psoriasis.10,11
Genetic variants in CARD14 have also been implicated as dis-
ease-causing/disease-contributing factors in patients with GPP
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and PPP;12–15 in vitro experiments of most of these variants sug-
gest an activation of nuclear factor kappa B (NF-jB).12,13 Two
missense variants in AP1S3 have further been described to con-
tribute to ACH, GPP and PPP6,16 and in vitro analysis suggests a
reduced protein function resulting in disruption of keratinocyte
autophagy and an increased activation of NF-jB leading to
upregulation of IL-1 signalling and overexpression of IL-36a.6,16
Because for IL36RN and AP1S3 genetic variants have been
shown to lead to a reduced function/loss of function of the
corresponding protein, copy-number variants (CNVs) affecting
coding parts of genes were considered as candidate variants.
However, screening for CNVs has rarely been included in
genetic studies of pustular skin diseases.8,14
To better understand the disease relevance of the three
genes, we screened our patient cohorts with pustular skin dis-
eases for qualitative coding variants in the three genes and
copy-number variants of coding exons in IL36RN and AP1S3.
In addition, we performed genotype–phenotype correlations
in carriers/noncarriers of IL36RN mutations within the GPP
cohort. Finally, heterozygous carriers of a single IL36RN muta-
tion were analysed for noncoding rare variants in IL36RN as
candidates for a second disease-causing variant.
Patients and methods
Patients
We screened our patient cohorts with pustular skin diseases
for coding variants in three genes. These cohorts comprised
61 patients with GPP, two with AGEP and four with ACH, as
well as 258 patients with PPP. Individual characteristics of the
participants with GPP, AGEP and ACH patients are listed in
Table S1 (see Supporting Information). The patient groups
were enlarged compared with previous studies,8,14 including
55 additional patients (n = 42 for GPP, n = 2 for AGEP, n = 4
in ACH, n = 7 for PPP).
All patients’ diagnoses were made by certified dermatologists
according to current knowledge of diseases; the majority of
patients with pustular psoriasis had been known to the recruit-
ing centres over longer periods of time before recruitment.
Patients with pustular skin disease as a possible paradoxical reac-
tion to a biological treatment were excluded from participation
in this study. The diagnosis of PPP was made on the basis of the
typical clinical picture, and only patients with unequivocal PPP
were included in the study. The diagnosis of ACH was also
made clinically by means of a disease course supporting the
diagnosis (e.g. chronic disease course, negative bacterial swabs
or lack of response to antibiotic therapy and treatment response
to immunosuppressive drugs). The diagnosis of GPP was based
on the clinical picture, which often includes symptoms of con-
comitant systemic inflammation and hypoparathyroidism or
hypocalcaemia, and was chronic or recurrent in all but four out
of 61 cases (Table S1). AGEP was also diagnosed clinically and
made in cases of patients with a single episode of a pustular rash
in the presence of a suspicious drug or the absence of a personal
or family history of psoriasis.
Most of the patients with GPP were of European origin
(n = 51), while in sum, 10 patients were from other regions
of the world (four patients from Turkey, one from Syria, one
from Morocco, one from Palestine, one from a foreign coun-
try not further specified, and two patients had grandparents
from Iraq) (Table S1). All patients with AGEP and ACH except
patient AGEP01 (Siberia) were of European origin (Table S1).
Within the group of 258 patients with PPP, four patients were
not of European origin (two from Turkey, one from Africa
and one from a foreign country not further specified). As pre-
viously reported,8 of the 254 European patients in the PPP
group there were 34 Estonians.
Molecular analyses
Patients with GPP, AGEP and ACH were sequenced for all cod-
ing exons of IL36RN and CARD14 as described previously,14
and we included previously published genetic data on sub-
groups of our cohorts in the present analyses. In addition, we
analysed the 325 patients (including the PPP group) for all
coding exons of AP1S3 by Sanger sequencing. The seven newly
included patients with PPP were screened for coding variation
in IL36RN and CARD14. Furthermore, we sequenced 11
heterozygous carriers of IL36RN mutations for noncoding
exons, intronic sequences, the 3ʹ untranslated region (UTR, in
sum ~58 kilobases) as well as upstream of the gene (245
kilobases) by Sanger sequencing using 26 overlapping poly-
merase chain reaction products.
In addition, a quantitative analysis of all coding parts of
IL36RN was performed on all patients’ DNA as described previ-
ously,14 and we established a new quantitative multiplex liga-
tion-dependent probe amplification test for all coding exons
of AP1S3 according to the recommendations of the manufac-
turer (MRC-Holland, Amsterdam, the Netherlands).17 Detailed
phenotypic data from the patients with GPP, AGEP and ACH
allowed for genotype–phenotype correlations (Table S1).
Comparison with controls and statistical analyses
We analysed frequencies of all identified variants in the cur-
rently largest possible control cohort of European individuals
and excluded variants with a minor allele frequency of > 2%.
As a result of low frequencies of coding variants, Fisher’s
exact test was applied to determine allele frequency differences
between exclusively European individuals and controls. Fish-
er’s exact test was also applied to determine differences
between carriers of IL36RN mutations and wild-type carriers.
The Wilcoxon rank test was used for comparison of age at
onset between those carriers and noncarriers of IL36RN muta-
tions. All statistical analyses were performed with the software
R (http://www.r-project.org/).18
Molecular modelling
Molecular modelling of variants in IL36RN was investigated on
the basis of a high-resolution crystal structure of a loop-
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swapped IL-36Ra (PDB: 4P0L).19 The swapped loops are
located distally from the sites of mutations investigated in the
present study, and therefore the respective structure was con-
sidered as a suitable model for wild-type IL-36Ra. The
p.Val44Met exchange was modelled with Swiss-PDB-Viewer
(https://spdbv.vital-it.ch/)20 and the lowest-energy rotamer
was selected for the Met44 side chain. The Thr99/Phe100
deletion was modelled with ModLoop (https://modbase.-
compbio.ucsf.edu/modloop/).21,22 In the case of the
p.Thr22Ala variant in AP1S3, its effect was modelled using
Swiss-PDB-Viewer based on the known crystal structure (PDB:
4HMY).23 RasMol (http://www.openrasmol.org/)24 was used
for structure analysis and visualization of both proteins.
Further assessments of rare variants
Rare variants were classified as disease-relevant or -irrelevant
according to previously published experimental data and/or to
results of molecular modelling as described previously14 includ-
ing previously unreported variants (see above). In addition, to
assess all missense variants in IL36RN further, we used dbNSFP
v20 (https://sites.google.com/site/jpopgen/dbNSFP)25 result-
ing in a combination of different protein prediction tools. In case
of the inframe deletion c.295-300delACCTTC/p.Thr99_
Phe100del, the combined annotation dependent depletion
(CADD) score was generated with the CADD tool (http://
cadd.gs.washington.edu/info).26 Furthermore, we interpreted
all missense variants identified and the inframe deletion in
IL36RN according to the American College of Medical Genetics
and Genomics (ACMG) standards and guidelines with the
Genetic Variant Interpretation Tool (http://www.medschool.
umaryland.edu/Genetic_Variant_Interpretation_Tool1.html/).27
Those criteria included, for example, the previous study by Tau-
ber et al.28 providing substantial evidence for functional effects
in in vitro analyses, their rarity in large exome sequencing projects
(Table S2; see Supporting Information) as well as their detection
in transwith a pathogenic variant.
Results
Generalized pustular psoriasis
The majority (n = 43, 71%) of patients with GPP were female;
five patients had received the diagnosis of GPP as one of several
differential diagnoses (Table S1). The mean age at recruitment
was 475  175 years, the mean age of disease onset
334  224 years. The majority of patients did not carry a rare
nonsynonymous variant in any of the three investigated genes
(64%, Fig. 1a), but rare nonsynonymous IL36RN variants were
identified in 20 patients with GPP (33%), biallelic IL36RN muta-
tions in 15 patients with GPP (25%) and single mutations in five
individuals (8%) (Table S1). A total of 11 different mutations
were detected (Fig. 1b). The most frequent mutation was
c.333>C>T (p.Ser113Leu) followed by c.227C>T (p.Pro76Leu).
We identified four variants in IL36RN so far unreported in pustu-
lar psoriasis: c.338C>A (p.Ser113X), c.295-300delACCTTC
(p.Thr99_Phe100del), c.130G>A (p.Val44Met) and c.308G>A
(p.Arg103Gln) (Table S1). According to molecular modelling,
c.338C>A (p.Ser113X) resulted in a shortened, destabilized
protein analogous to c.280G>T (p.Glu94X).14Val44 is located
in the hydrophobic core of IL-36Ra (Fig. 2a).In the Val44Met
variant, the longer Met44 side chain causes steric clashes with
Phe151 (Fig. 2b), which are expected to decrease protein sta-
bility. Arg103 is solvent-exposed in the IL-36RA structure and
does not form any specific interactions with the adjacent side
chains. Thus, mutation of Arg103 appears less critical than
that of the adjacent R102, which forms numerous stabilizing
interactions. This is in line with the sequence-based classifica-
tion that predicts the Arg102Trp more critical than the
Arg103Gln exchange.
Thr99 and Phe100 are rather buried in the IL-36Ra struc-
ture and form tight interactions with adjacent residues
(Fig. 2c). Modelling suggests that upon deletion of Thr99/
Phe100 the respective spatial positions become occupied by
the N-terminally adjacent residues Ser97/Phe98, which would
allow Phe98 to establish the same crucial interactions observed
for Phe100 in the wild-type (Fig. 2c, d). Ser97 lacks the side-
chain methyl group present in Thr99, which results in a loss
of hydrophobic interactions with Pro56 (Fig. 2c, d). How-
ever, the strongest loss of stability is observed around the site
at which Phe98 is located in the wild-type. Phe98 forms tight
hydrophobic contacts with Val83 and Leu88 in the wild-type
protein thereby stabilizing the position of the respective helix
(Fig. 2c). In the deletion mutant, Lys96 is shifted to the
respective position of the IL-36Ra structure (Fig. 2d), which
causes a loss of the hydrophobic contacts and which is
expected to cause a decrease in protein stability. Therefore,
c.130G>A (p.Val44Met) and c.295-300delACCTTC
(p.Thr99_Phe100del) were also predicted to result in destabi-
lized, likely disease-relevant, loss-of-function proteins (Fig. 2).
When we applied further assessments of those rare genetic
variants using protein prediction programs, we observed fewer
harmful predictions in the case of c.130G>A (p.Val44Met)
compared with other known disease-causing variants (Table S3;
see Supporting Information). Interestingly, the same analyses
for some of the established harmful rare missense variants in
IL36RN such as c.333>C>T (p.Ser113Leu) – shown to result in
reduced protein levels in in vitro analyses28 – did not provide evi-
dence for a harmful effect with the majority of algorithms. Fur-
thermore, as pathogenicity of rare coding variants in a
monogenic disease cannot be predicted by using those algo-
rithms alone, we assessed the pathogenicity of so far unreported
rare variants – including the inframe deletion – by using ACMG
standards and guidelines. Thereby, the variants c.130G>A
(p.Val44Met) and c.295-300delACCTTC (p.Thr99_Phe100del)
were classified as likely pathogenic (class IV variants) and
c.308G>A (p.Arg103Gln) was classified as a variant of
unknown significance. As this latter classification neither
excludes nor proves a disease-causing status and the overall
proportion of this variant in the sum of mutated IL36RN
alleles was minor, we stayed with this variant for further
analyses.
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Heterozygous AP1S3 mutations were detected in two
patients with GPP, both of whom carried additional homozy-
gous or compound-heterozygous IL36RN mutations (Fig. 1a,
Table 1, Table S1). A daughter of a consanguineous marriage
carried a homozygous IL36RN mutation as well as the
homozygous AP1S3 variant c.64A>G (p.Thr22Ala) [minor
allele frequency in Exome Aggregation Consortium (120 618
alleles): 017%]. According to molecular modelling, the Ala22
mutant protein loses two intermolecular contacts, weakening
the interaction between the c-1 chain and the r-3 chain
(Fig. S1). Although potentially relevant in a homozygous state,
the variant was excluded from statistical analyses, as it is prob-
ably less functionally relevant than the c.11T>G (p.Phe4Cys)
and c.97C>T (p.Arg33Trp) variants identified previously.6
Furthermore, none of the used protein prediction tools con-
sidered this effect as harmful, confirming a previous analysis6
and strengthening our strategy of exclusion. Heterozygous rare
missense variants in CARD14 were identified in four patients
with GPP; but we excluded c.599G>A (p.Ser200Asn) from
further analysis, as it has been described to be a missense vari-
ant without significantly differential effects on activation of
NF-jB in comparison with wild-type.29 One of the further
three missense variants has been previously associated with
GPP and PPP.8,12,15 Of note, one of the three patients
(GPP18) carried an additional mutation in IL36RN (Fig. 1a,
Table S1).
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Fig 1. Mutations in IL36RN and clinical
correlations in 61 patients with generalized
pustular psoriasis (GPP). (a) Venn diagram
indicating overall number of carriers of
mutations in IL36RN, of rare variants in AP1S3
or CARD14, of carriers of rare variants in two
of these genes and of noncarriers of a variant
in any of the three genes in patients with
GPP. (b) Distribution of IL36RN mutations in
61 patients with GPP. * indicates the only
rare variant classified as a variant of unknown
significance. (c) Correlation of mutation status
in IL36RN (x-axis) with age at manifestation
(y-axis). ‘2 Mutations’ indicates carriers of
mutations on both gene copies, ‘1–2
Mutations’ carriers of a single mutation as
well as carriers of mutations on both gene
copies, and ‘wild-type’ carriers are those with
no IL36RN mutations.
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Other pustular skin diseases
For AGEP, both patients carried a heterozygous variant in AP1S3;
in ACH, two of the four patients carried a heterozygous muta-
tion in IL36RN (Table S1). Clinical characteristics of the patients
with PPP (Table S4) were very similar to the ones reported in a
largely overlapping group in PPP; 13 of 258 patients were
heterozygous carriers harbouring one of the two nonsynony-
mous changes in AP1S3 (Table 1). Variant c.95C>T (p.Thr32Ile)
was identified in two patients in the PPP group, but not
included in further analyses, as molecular modelling did not
predict a clear functional impact.
Association and quantitative analyses
Overall, we observed a highly significant association of pustu-
lar skin disease with IL36RN variants (P < 22 9 1016) and a
significant association of GPP with CARD14 variants
(31 9 1004) (Table 1). In contrast, we did not find any
evidence of an association between AP1S3 variants and GPP,
ACH or PPP (Table 1), and the groups of patients with AGEP
and ACH on their own (n = 2 and 4, respectively) are too
small to draw any conclusions. By excluding c.599G>A
(p.Ser200Asn) as a probably nonfunctional variant, association
of PPP with coding variants in CARD14 was no longer identi-
fied.8 None of our patients was found to carry an intragenic
deletion or duplication in IL36RN (n = 325) or the coding
regions of AP1S3 (n = 322), with quantitative analysis of
AP1S3 not resulting in reliable copy number results in three
patients with PPP.
Analysis of noncoding regions of IL36RN
By sequencing the noncoding parts of IL36RN in all carriers
of a single heterozygous mutation (n = 11) identified in the
current study or in a previous analysis of patients with PPP,8
we did not detect a single rare variant. These results in com-
bination with the lack of disease-causing intragenic CNVs
render a disease-relevant variant on the second IL36RN allele
unlikely.
Genotype–phenotype correlation in generalized pustular
psoriasis
Our genotype–phenotype correlation revealed a similar sex
distribution in carriers of IL36RN mutations and wild-type car-
riers, but a strong association between biallelic mutations in
IL36RN and early age of manifestation (P = 74 9 1004).
Also, the group of both carriers of single IL36RN mutations as
well as of carriers of compound-heterozygous/homozygous
mutations had a significantly younger age at onset vs. noncar-
riers (P = 69 9 1003, Fig. 1c). We did not observe a signif-
icant difference in the frequency of accompanying psoriasis
vulgaris in carriers/noncarriers of IL36RN mutations (Table 2).
As in other autosomal recessively inherited mutations, the fre-
quency of parental consanguinity was significantly higher in
patients with two IL36RN mutations compared with noncarri-
ers (Table 2). Furthermore, in patients with GPP, we observed
no difference in carriers/noncarriers of IL36RN mutations with
respect to frequency of episodic vs. continuous course of dis-
ease, positive family history for either psoriatic or rheumatic
(a) (b)
(c) (d)
Fig 2. Molecular modelling of novel variants
in IL36Ra. Effect of the Val44Met exchange
and the Thr99/Phe100 deletion on the
structure of IL36Ra. (a) Val44 is located in
the hydrophobic core of the molecule. (b)
Met44 forms clashes with Phe151 that are not
present in the wild-type. The side chains of
residues 44 and 151 are shown in space-
filling presentation and steric clashes are
indicated by red arrows. (c) Location and
interaction of residues Phe98, Thr99 and
Phe100 (all shown in space-filling
presentation) in the wild-type. Hydrophobic
interactions between Thr99 and Pro56 as well
as Phe98 and Val83/Leu88 are denoted with
a green arrow and circle, respectively. (d)
Thr99/Phe100 mutant, in which Phe98
occupies the position of Phe100 from the
wild-type. Note the loss of hydrophobic
interactions of residues Lys96/Ser97
compared with Phe98/Thr99 in the wild-
type.
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disease or frequency of other accompanying manifestations
such as PPP, nail, joint or tongue involvement (Table 2).
Discussion
In the majority of patients with GPP, we did not identify a
causal variant, indicating a role of further disease-causing/dis-
ease-contributing genes. To the best of our knowledge, a
comprehensive analysis of the three genes has not been
reported in larger patient groups of patients with pustular pso-
riasis. With regard to the genes AP1S3 and CARD14, our results
suggest their variants have a much lower impact in GPP than
variants in IL36RN.
Of note, in the currently largest European control cohort, the
sum of the allele frequencies of the two AP1S3 missense variants
c.11T>G (p.Phe4Cys) and c.97C>T (p.Arg33Trp) was 1%
higher (23% in 32 864 Non-Finnish European individuals in
the Exome Aggregation Consortium) than described in the ini-
tial study by Setta-Kaffetzi et al.6 (13% in 1695 control
exomes), possibly explaining why associations of these variants
had been previously identified. All current studies performed
for the AP1S3 gene are underpowered to detect associations in
this frequency range, but more importantly, the study by Setta-
Kaffetzi et al.6 followed by the one of Mahil et al.16 indicated
that those variants were functional. Nevertheless, those variants
have been described as less penetrant susceptibility alleles in
contrast to the mutations in IL36RN. Our finding of two
heterozygous carriers of AP1S3 disease-contributing variants
within the small group of only two patients with AGEP is an
interesting one and might hint to be a relevant variant in a
broader disease spectrum, although it needs further confirma-
tion within a larger patient cohort to be a significant one.
Apart from a missense variant in mainly Asian cohorts of
patients with GPP,12,15 variants in CARD14 were relevant in sin-
gle patients with GPP and were overall associated, but do not
seem to play a major role in the group of European patients. In
addition, the more recent interpretation of a single missense
variant in CARD1412 renders our previous association of PPP
with missense variants in CARD148 a nonsignificant one.
As recently reported,3 carriers of IL36RN mutations were
significantly younger at age of onset than noncarriers. In dis-
agreement with previous studies,3,15 frequencies of patients
with concomitant psoriasis vulgaris were comparable between
the two groups. Although considerable additional clinical data
were collected, no associations of IL36RN with other clinical
characteristics were observed.
When sequencing noncoding regions of IL36RN, no evi-
dence for additional noncoding mutations in carriers of a
Table 1 Association analysis of different pustular skin diseases with rare variants in AP1S3, CARD14 and IL36RN in European individualsa
Gene, variant
GPP
(n = 51)
AGEP
(n = 1)
ACH
(n = 4)
PPP
(n = 254)
∑ Pustular
psoriasis
phenotypes (n = 310) Control groupb
AP1S3
c.11T>G (p.Phe4Cys) 1 (10) 0 (0) 0 (0) 10 (20) 11 (18) 778 (12)
c.97C>T (p.Arg33Trp) 1 (10) 1 (05) 0 (0) 3 (06) 5 (08) 724 (11)
∑ mutant alleles 3 (27) 13 (26) 16 (26) 1,502 (23)
∑ wild-type alleles 109 (973) 495 (974) 604 (974) 64 226 (977)
P-value 074 065 059
CARD14
c.206G>A (p.Arg69Gln) 1 (10) 0 (0) 0 (0) 0 (0) 1 (015) 1 (0007)
c.349G>A (p.Gly117Ser) 1 (10) 0 (0) 0 (0) 0 (0) 1 (015) 0 (0)
c.526G>C (p.Asp176His) 0 (0) 0 (0) 0 (0) 2 (04) 2 (031) 7 (005)
c.536G>A (p.Arg179His) 1 (10) 0 (0) 0 (0) 0 (0) 1 (015) 3 (002)
∑ mutant alleles 3 (27) 2 (04) 5 (08) 11 (008)
∑ wild-type alleles 109 (973) 506 (996) 615 (992) 13 519 (9992)
P-value 18 9 1004 008 46 9 1004
IL36RN
Mutant alleles 25 (245) 0 (0) 2 (025) 3 (06) 30 (48) 358 (054)
∑ mutant alleles 27 (241) 3 (06) 30 (48) 358 (054)
∑ wild-type alleles 85 (759) 505 (994) 590 (952) 65 384 (9946)
P-value < 22 9 1016 076 < 22 9 1016
Numbers indicate absolute allele counts (percentages). w/o, without. aMutant and wild-type alleles of variants in 51 patients with general-
ized pustular psoriasis (GPP), one with acute generalized exanthematous pustulosis (AGEP) patient, four with acrodermatitis continua of Hal-
lopeau (ACH), 254 with palmoplantar pustular psoriasis (PPP) and (database) controls as well as results of association analysis are shown.
b32 864 Non-Finnish European individuals in the publicly available database, Exome Aggregation Consortium (ExAC, http://exac.broadinsti-
tute.org/),30 with available genotypes of the two AP1S3 variants, including 12 homozygous carriers of c.11T>G (p.Phe4Cys) and three
homozygous carriers of c.97C>T (p.Arg33Trp) and of the IL36RN mutations (see also Table S2; see Supporting Information). Coverage of
CARD14 in ExAC was not as good as in AP1S3 and IL36RN, therefore a combination of different control groups was used, similarly as
described in Mossner et al.8 and indicated in detail in Table S5 (see Supporting Information).
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single heterozygous IL36RN mutation was found. Also, the
quantitative analysis rendered an intragenic deletion or dupli-
cation on the second allele unlikely. The frequency of
heterozygous carriers of IL36RN mutations (8%) is much
higher (15 times) than the frequency of heterozygous carri-
ers in the general population (054%). Additionally, none of
the parents of our GPP patients, carrying a heterozygous
IL36RN mutation, had pustular skin disease. These findings
suggest a contributing effect of the IL36RN mutations in
heterozygous patients with pustular psoriasis, and a more
complex, probably oligogenic inheritance. An oligogenic
rather than a purely monogenic inheritance is further sup-
ported by IL36RN mutations occurring with additional vari-
ants in other genes in 15% of those carriers. Previously,
epistatic effects of IL36RN and AP1S3 have been suggested in
a single European patient carrying one IL36RN mutation and
one of the two missense variants in AP1S3.16 To our knowl-
edge, more comprehensive studies in larger study groups
have not been performed. The oligogenic basis of GPP might
currently be underestimated, as our study suggests that
genetic risk factors other than IL36RN mutations remain to
be identified in the majority of patients.
In conclusion, our systematic analysis of genotype–pheno-
type correlations suggests a very significant correlation of
IL36RN mutations with a younger age at disease onset, with
no further significant correlations observed. Patients with GPP,
with IL36RN mutations, carried an additional rare variant in
either CARD14 or AP1S3 in 15% of cases, indicating a more
complex inheritance. Additional genetic factors outside IL36RN
probably contribute to the pathogenesis of pustular skin dis-
ease in heterozygous IL36RN mutation carriers.
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carriers of one to two
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(n = 20)
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noncarriers of
IL36RN mutation
(n = 41)
P-value
(A vs. C)
P-value
(B vs. C)
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Male 4 (27) 5 (25) 13 (32) 1 076
Female 11 (73) 15 (75) 28 (68)
Course of diseasea
Episodic 13 (93) 15 (83) 26 (70) 014 034
Continuous 1 (7) 3 (17) 11 (30)
Palmoplantar pustular psoriasis
Yes 3 (20) 5 (25) 4 (10) 036 013
No 12 (80) 15 (75) 37 (90)
Tongue affectedb
Yes 4 (27) 5 (25) 8 (21) 071 074
No 11 (73) 15 (75) 31 (79)
Psoriasis vulgarisc
Yes 3 (20) 5 (25) 20 (50) 0066 0095
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